Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic Study of Multiferon in Early-Stage Primary Myelofibrosis
2011-005414-10Phase 2Completed
- Sponsor
- Nordic Myeloproliferative Neoplasm Group
- Start
- Feb 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in primary myelofibrosis (PMF), sponsored by Nordic Myeloproliferative Neoplasm Group. Primary endpoints: Bone marrow fibrosis regression and/or normalization at 1 year and Bone marrow fibrosis regression and/or normalization at 2 years. Started Feb 2012; status: completed.
02
Drugs
interferon alfa
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2011-005414-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005414-10.